论文部分内容阅读
目的探讨硫普罗宁联合奥沙利铂对肿瘤的临床疗效和用药安全性。方法通过对本院2006年1月至2011年9月病理证实肺癌患者60例使用奥沙利铂130 mg/m2,静脉滴注2 h,第1和第8天硫普罗宁0.2 g配5%的葡萄糖注射液250 ml,静脉滴注,1次/d。治疗前后给予止吐药,21～28 d为一个周期,2个周期后对患者病情进行一次评估。结果 60例患者其中CR 6例(10%),PR 23例(38.33%),SD 25例(41.67%),PD 6例(10%),总有效率48.33%;该药物组合的主要毒副作用是骨髓抑制和胃肠道反应。结论硫普罗宁联合奥沙利铂对肺癌疗效好,副作用小,临床上值得推广。
Objective To investigate the clinical efficacy and safety of tiopronin combined with oxaliplatin on tumor. Methods The hospital from January 2006 to September 2011 pathologically confirmed 60 cases of lung cancer patients with oxaliplatin 130 mg / m2, intravenous infusion of 2 h on the 1st and 8th Tiopronin 0.2 g with 5% Glucose injection 250 ml, intravenous infusion, 1 time / d. Before and after treatment given antiemetic drugs, 21 ~ 28 d for a cycle, two cycles after the patient’s condition to conduct an assessment. Results Sixty patients (10%), PR 23 (38.33%), SD 25 (41.67%) and PD 6 (10%) had a total effective rate of 48.33%. The main toxicities and side effects of the drug combination Is myelosuppression and gastrointestinal reactions. Conclusion Sipoprofen combined with oxaliplatin has good curative effect on lung cancer and little side effects, which is worth to be popularized clinically.